Valion Bio, Inc. (VBIO)
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Valion Bio, Inc.
Trials need funding. See this company's dilution risk and cash position.
- ObservationalCompleted
A User Study of SYNUS Pain Relief Made by Tivic Health Systems
SYNUS Pain Relief device
Sinus; Inflammation
NCT03466879Enrollment72StartFeb 2018Primary CompletionJul 2018CompletionJul 2018 - Not applicableCompleted
ClearUP Longitudinal Pilot Study
ClearUP Sinus Pain Relief
Sinus Pain, Congestion
NCT03888274Enrollment30StartNov 2018Primary CompletionFeb 2019CompletionMar 2019
| Drug / Therapy | Link | ||
|---|---|---|---|
| Observational | Completed | SYNUS Pain Relief device | NCT03466879 |
| Not applicable | Completed | ClearUP Sinus Pain Relief | NCT03888274 |